• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Stromedix

edit

Stromedix will focus initially on chronic indications but plans to leverage its expertise and expand its therapeutic pipeline into related settings such as acute organ failure and cancer.

Recent Milestones

edit

• 
  Stromedix — has taken in $2 million of a planned $15.5 million new financing round (1/26/11)
  Posted 1/26/11 at 6:29am via masshightech.com
• 
  Stromedix received $2M in Series C funding. (1/26/11)
  Posted 1/26/11 at 7:03pm via masshightech.com
• 
  Stromedix received $25M in Series B funding. (4/21/08)
  Posted 6/3/09 at 10:22pm
• 
  Stromedix received $1M in Series A funding. (3/22/07)
  Posted 3/19/10 at 11:40pm
• 
  Stromedix added Michael Gilman as Founder and CEO.
  Posted 6/3/09 at 10:22pm
• 
  Stromedix added Brad Maroni as Chief Medical Officer.
  Posted 6/3/09 at 10:22pm
• 
  Stromedix added Shelia Violette as Vice President, Research.
  Posted 6/3/09 at 10:22pm
• 
  Stromedix added Dan Lynch as Executive Chairman.
  Posted 6/3/09 at 10:22pm

Videos

Screenshots

edit

Above: Homepage
Uploaded: 6/4/09

Sources

1. EDGAR [edit]
2. Capital Funding Report [edit]
3. Stromedix lands $2M, looks for $15.5M in new funding (masshightech.com) [edit]
Stromedix lands $2M, looks for $15.5M in new funding (masshightech.com) [edit]